| Name | Title | Contact Details |
|---|
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Bodycad helps healthcare professionals and patients achieve their common pursuit of perfection by actualizing personalized orthopedic restorations. Bodycad enables orthopedic surgeons to create a personalized restoration based on the anatomical specifications of their patient using the company`s proprietary Personalized Restoration Software. Surgeons can quickly and efficiently step through the Bodycad PREP (Personalized Restoration Evaluation Process) to scan their patients and create a specific design plan, approve the design, and perform the restoration. The company is committed to providing high-touch education, training and service, including access to Bodycad PREP Techs to help assure surgical success. Bodycad is transforming the current standard of orthopedic implants to help surgeons and patients achieve their mutual goal of a perfect personalized restoration.
Keating Dental Arts is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Augmenix, Inc. is a privately held Company based in Waltham, MA focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. The company was founded by Incept LLC in 2008 and is funded by several leading venture capital groups.